Beneficial Effects of Human Schwann Cell-Derived Exosomes in Mitigating Secondary Damage After Penetrating Ballistic-Like Brain Injury

Kengo Nishimura,Juliana Sanchez,Nadine Kerr,Yelena Pressman,Risset Silvera,Aisha Khan,Shyam Gajavelli,Helen M Bramlett,W Dalton Dietrich,Helen M. Bramlett,W. Dalton Dietrich
DOI: https://doi.org/10.1089/neu.2023.0650
IF: 4.869
2024-03-07
Journal of Neurotrauma
Abstract:There is a growing body of evidence that the delivery of cell-derived exosomes normally involved in intracellular communication can reduce secondary injury mechanisms after brain and spinal cord injury and improve outcomes. Exosomes are nanometer-sized vesicles that released by Schwann cells may have neuroprotective effects by reducing posttraumatic inflammatory processes as well as promoting tissue healing and functional recovery. The purpose of this study was to evaluate the beneficial effects of human Schwann-cell exosomes (hSC-Exos) in a severe model of penetrating ballistic-like brain injury (PBBI) in rats and investigate effects on multiple outcomes. Human Schwann cell processing protocols followed Current Good Manufacturing Practices (cGMP) with exosome extraction and purification steps approved by the FDA for an expanded access single ALS patient IND. Anesthetized male Sprague-Dawley rats (280-350g) underwent PBBI surgery or sham procedures and starting 30 min after injury received either a dose of hSC-Exos or PBS through the jugular vein. At 48hrs after PBBI, flow cytometry analysis of cortical tissue revealed that hSC-Exos administration reduced the number of activated microglia and levels of caspase-1, a marker of inflammasome activation. Neuropathological analysis at 21 days showed that hSC-Exos treatment after PBBI significantly reduced overall contusion volume and decreased the frequency of Iba-1 positive activated and amoeboid microglia by immunocytochemical analysis. This study revealed that the systemic administration of hSC-Exos is neuroprotective in a model of severe TBI and reduces secondary inflammatory injury mechanisms and histopathological damage. The administration of hSC-Exos represents a clinically relevant cell-based therapy to limit the detrimental effects of neurotrauma or other progressive neurological injuries by impacting multiple pathophysiological events and promoting neurological recovery.
neurosciences,clinical neurology,critical care medicine
What problem does this paper attempt to address?